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Abstract
Background: Consumption of plant sterols has been reported to reduce low density lipoprotein (LDL)
cholesterol concentrations by 515%. Factors that affect plant sterol efficacy are still to be determined.
Objectives: To more precisely quantify the effect of plant sterol enriched products on LDL cholesterol
concentrations than what is reported previously, and to identify and quantify the effects of subjects’
characteristics, food carrier, frequency and time of intake on efficacy of plant sterols as cholesterol lowering
agents.
Design: Fifty-nine eligible randomized clinical trials published from 1992 to 2006 were identified from five
databases. Weighted mean effect sizes were calculated for net differences in LDL levels using a random effect
model.
Results: Plant sterol containing products decreased LDL levels by 0.31 mmol/L (95% CI, 0.35 to
0.27, PB0.0001) compared with placebo. Between trial heterogeneity was evident (Chi-square test,
PB0.0001) indicating that the observed differences between trial results were unlikely to have been caused
by chance. Reductions in LDL levels were greater in individuals with high baseline LDL levels compared with
those with normal to borderline baseline LDL levels. Reductions in LDLwere greater when plant sterols were
incorporated into fat spreads, mayonnaise and salad dressing, milk and yoghurt comparing with other food
products such as croissants and muffins, orange juice, non-fat beverages, cereal bars, and chocolate. Plant
sterols consumed as a single morning dose did not have a significant effect on LDL cholesterol levels.
Conclusion: Plant sterol containing products reduced LDL concentrations but the reduction was related to
individuals’ baseline LDL levels, food carrier, and frequency and time of intake.
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D
ietary incorporation of plant sterols and stanols
is recommended for blood cholesterol reduction
(1, 2). Berger et al. reviewed clinical trials on
efficacy of plant sterols as cholesterol lowering agents and
reported that the consumption of plant sterols/stanols
have been reported to reduce low density lipoprotein
(LDL) cholesterol levels by 515% (3). Reasons for such
large variations need to be investigated.
Earlier studies that have tested the efficacy of plant
sterols/stanols as cholesterol lowering agents incorporated
plant sterols/stanols into either regular or low fat spreads
(813). Since it appears counterintuitive to use a high fat
food product to deliver a cholesterol lowering agent,
clinical trials have been conducted to test the efficacy of
plant sterols/stanols incorporated into low fat products
(14). A number of clinical trials have tested the efficacy of
plant sterols/stanols incorporated into low fat foods
including low fat milk (15, 16), low fat yoghurt (1620),
bakeryproducts(21),orangejuice(22,23),cerealbars(24)
and low and non-fat beverages (2527). However,
although plant sterols/stanols that are incorporated into
low fat food have been shown to reduce blood cholesterol
(24, 27, 28), the same food carrier tested in different trials
gave different magnitude in LDL cholesterol reduction.
Plant sterol/stanol enriched yoghurt and milk drinks have
resulted in LDL cholesterol reduction in the range of
514% in various clinical trials (29). The study by Clifton
et al. (30) compared the effect of plant stanol esterified to
fatty acids and incorporated in a number of food matrices
including bread, breakfast cereal, milk and yoghurt on
plasma lipids. Plant stanol esters in low fat milk were
almost three times more effective than in bread and cereal
(page number not for citation purpose)
 Meta-analysis
Food & Nutrition Research 2008. # 2008 AbuMweis S. S. et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution-
Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited. Citation: Food & Nutrition Research 2008.
1
DOI: 10.3402/fnr.v52i0.1811in lowering plasma cholesterol levels. Whether all plant
sterols/stanols enriched low fat food matrices are effica-
cious as plant sterol/stanol enriched spread carrier in
lowering blood cholesterol has not been studied thor-
oughly. It remains to be determined which food matrices
are viable carriers to deliver an effective dose of plant
sterols/stanols.
The optimal number of servings per day of plant sterol/
stanol containing products was addressed in only one
study. Plat et al. (31) showed that 2.5 g of plant stanols in
margarines and shortenings consumed for four weeks
once per day at lunch or divided over three meals,
lowered LDL cholesterol levels to a similar extent, about
10%. The intake of a single dose of plant sterol/stanol
enriched products is thought to increase consumers’
compliance and adds convenience. However, further
studies using a single dose of plant sterols/stanols
consumed either at breakfast (18, 19, 32), or with lunch
or the principal meal (19, 31, 33, 34) yielded conflicting
results. For example, when plant sterol enriched margar-
ine was consumed with breakfast, no reduction in
cholesterol levels was observed (32), in spite of the
previously demonstrated efficacy as a single serving at
lunch (31). In another study, intake of the single dose of
plant sterols provided in yoghurt drinks with lunch
resulted in a larger decrease in LDL levels than the
intake of same dose of plant sterols provided 30 min
before breakfast (19). Since plant sterol/stanol products
are being marketed for consumption once a day, it
remains to be investigated whether the effect of single
dose of plant sterols/stanols consumed at different time of
the day is comparable to that consumed as multiple
dosages throughout the day.
Several potential modifiers for the effect of plant sterol/
stanol supplementation on reduction of LDL levels were
studied in some trials, including age and gender, baseline
LDL levels, and genetic profile. Again, results from
various studies are inconsistent. For example, baseline
LDL levels have been shown to modify the effect of plant
sterols/stanol in some (35, 36), but not other studies
(8, 37, 38). Furthermore, identification of effect modifiers
in the cholesterol lowering action of plant sterols/stanol
will help target individuals who may benefit more from
such an intervention.
Accordingly, instead of conducting additional rando-
mized clinical trials to resolve the disagreement surround-
ing the influence of the aforementioned factors on the
cholesterol lowering action of plant sterols/stanols, it was
considered that an appropriate meta-analysis could be
used as an alternative novel approach. Previous meta-
analyses have studied the efficacy of plant sterols/stanols
as cholesterol lowering agents. The first (4) looked at the
cholesterol lowering action of plant sterols/stanols added
to fat spreads mostly in the form of margarines. Another
(5)lookedat theefficacyandsafetyofplantsterols/stanols
as cholesterol lowering agents, but since 2003 a number of
clinical trials have examined the efficacy of low fat foods
containing plant sterols/stanols and observed substan-
tially weaker effects. A recent meta-analysis (6) sought to
investigate effects of plant sterols/stanol in lowering total
and LDL cholesterol levels of familial hypercholesterole-
mia subjects. Two previous meta-analyses conducted on
plant sterols/stanols were non-systematic reviews (4, 5),
which failed to describe how reviewers searched, selected
and evaluated the quality of studies. Narrative reviews are
qualitative summaries of a certain topic (7). While
systematic meta-analyses include a comprehensive search
of the primary studies on a specific clinical question,
selectionofstudiesbyusingcleareligibilitycriteria,critical
evaluation of the quality of studies, and generating results
using a pre-specified method (7).
Meta-analysis is a statistical tool that generates pooled
estimates of effects from the results of randomized
controlled trials (7). It is an unbiased tool to assess an
intervention and may lead to resolution of controversy.
Therefore, a systematic meta-analysis could resolve the
apparent controversy concerning the influences of food
carrier, frequency and time of intake, as well as subjects’
baseline characteristics on cholesterol lowering action of
plant sterols/stanols.
The objectives of the present meta-analysis were to
more precisely quantify the effect of plant sterol/stanol
enriched products on LDL cholesterol concentrations
and to identify and quantify the effect of subjects’
characteristics, food carrier, frequency and time of intake.
Materials and methods
Literature search
Studies that examined the efficacy of plant sterols/stanols
as cholesterol lowering agents in humans were identified
by searching five databases PubMed, Embase, Medline,
Cochrane Library and Web of Science using the terms
‘‘plant sterol’’, ‘‘plant stanol’’ ‘‘phytosterol’’ and ‘‘phyto-
stanol’’ as words in the title, abstract or keywords. When
available, the search was restricted to clinical trials. In
addition, a manual search using reference lists of review
articles (35, 39) was performed. For non-English lan-
guage literature, if available, the abstract written in
English was used to extract the required information;
otherwise the trial was not included in the analysis. All
citations were exported into reference manager software
(EndNote version 8.0.2) and studies on plant sterols/
stanols and cholesterol metabolism were identified. Fifty
nine eligible randomized clinical trials published from
1992 to 2006 were identified from the five databases.
Selection criteria
Randomized placebo controlled studies conducted to test
the efficacy of plant sterols/stanols incorporated into
S. S. AbuMweis et al.
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were included in this meta-analysis. Therefore, studies
were first excluded from the meta-analysis for not
measuring circulating LDL levels as a primary or
secondary outcome, for having duration of intervention
of less than two weeks, for examining children or adults
who were homo- or heterozygote for sitosterolemia or
who possessed a history of cardiovascular disease. Studies
were also excluded for having a co-intervention that
could not be separated from plant sterol/stanol treat-
ment, for incorporating plant sterols/stanols in the form
of capsule or tablets, or for not having a control group or
an appropriate control /placebo. In addition, studies were
excluded if lipid profiling was done on non-fasting blood
samples or if lipid profile data were published elsewhere.
A total of 84 clinical trials met the first inclusion criteria
and were then screened for the quality criteria (Fig. 1).
Quality assessment of trials
Randomized controlled studies were assessed for metho-
dological quality with the Jadad score as described in
Table 1 (40). A Jadad score of three or above, out of a
maximum of five, was used to indicate that a study is of
reasonablequalitytobeincludedinthemeta-analysis(41).
Data abstraction
All data were abstracted from the original articles. No
datawere directly obtained from the original authors. For
studies that met the inclusion criteria and that possessed
a Jadad score of equal or more than three, data were
extracted for parameters related to (i) trial design; (ii)
type of plant sterols/stanols; (iii) dose (g/day) and
duration of plant sterol/stanol treatment; (iv) frequency
and time of intake of plant sterols/stanols; (v) food
carrier, to which plant sterols/stanols were incorporate;
(vi) characteristics of the study population; (vii) the mean
values and the standard deviations (SD) of LDL choles-
terol levels; and (viii) sample size. Two reviewers (SSA
and RB) independently identified articles for inclusion,
assessed quality and extracted data.
Quantitative data synthesis
For studies that reported multiple time points for the
same subjects, only endpoints for the longest duration of
the intervention were used. For studies in which the
outcomes were presented as percentage change from
baseline, and no endpoint data were available (37, 42,
43), endpoint datawere imputed using the baseline values
and percentage change from baseline and the SD of the
baseline data for the endpoint SD. Where studies
Fig. 1. Selection of randomized placebo controlled studies for meta-analysis of plant sterols and circulating cholesterol levels.
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data were available (26, 44, 45), we imputed endpoints
using baseline plus change for the mean and using the SD
of the baseline data for the endpoint SD.
The primary outcome for this meta-analysis was the
difference in LDL cholesterol levels, reported in mmol/L,
due to plant sterol/stanol treatment. For parallel arm
designed trials, endpoint LDL cholesterol in the treatment
group was subtracted from endpoint LDL cholesterol in
the control group (46). We did not use differences in
changesfrombaselineastheprimaryoutcomebecausethis
would imply imputing SDs for changes from baseline for
themajorityofparallel studies,whichis notrecommended
(46). For crossover trials, the LDL cholesterol value at the
endofthetreatmentperiodwassubtractedfromthatatthe
end of the control period (46). Within-individual changes
were used when presented; otherwise, group means were
used. SDs were extracted from the studies or, if not
reported, derived from standards errors (SDs) of mean,
confidence intervals (CIs), paired t-value or P-value as
provided(46).Ifdifferenttreatmentsweretestedwithinthe
same trial, they were evaluated as separate strata, as is
described by ‘‘a, b, c and d’’suffixes in Tables and Figures.
To obtain the pooled treatment effect size (ES), estimates
and SE were entered into RevMan 4.2 under the ‘‘generic
inverse variance’’ outcome. Heterogeneity between trial
results was tested for using a standard chi-squared test. A
P-value B0.1 was used to indicate that significant
heterogeneity was present (46).
Calculations used in this meta-analysis are presented in
the Appendix. Estimates of the pooled treatment ES of
plant sterol/stanol containing food on LDL cholesterol
levels and 95% CIs were calculated by using both fixed
effect and random effect models. If the test for hetero-
geneity was significant, we presented the results of the
random effect models. Otherwise, estimated results based
on a fixed effect model are presented. We presented the
ES as mmol/L, and not as percentage difference, as most
of the studies did not report the SD of the percentage
difference in LDL values between the control and the
treatment group or phases. The presence of publication
bias was examined for using a funnel plot, in which the
SEs of the studies were plotted against their correspond-
ing ES.
Results
Fifty-nine studies comprising 95 relevant strata were
assessed as eligible for meta-analysis with  4500 sub-
jects. A summary of trial design and characteristics is
shown in Table 2 and Table 3. Twenty-nine studies
utilized a crossover design while 30 used a parallel design.
Sample sizes ranged from 8 to 185 subjects.
Individual trial results and the pooled ES for all trials
are shown in Fig. 2. In the overall pooled estimate, plant
sterol/stanol consumption decreased LDL levels by
0.31 mmol/L (95% CI, 0.35 to 0.27, PB0.0001)
compared with placebo. Between- trial heterogeneity was
evident (Chi-square test, PB0.0001; I
265%). It was
estimated that as 65% of the variability in the ES is due to
heterogeneity between the trials (clinical and methodo-
logical diversity) rather than chance. Thus, we performed
a subgroup analysis according to predefined criteria by
subjects’ characteristics and study design features as
summarized in Table 4. Initial serum LDL cholesterol
levels had a powerful effect on changes in lipid concen-
trations. Therefore, subjects were grouped into two
groups, one included subjects with high baseline levels
of LDL and the other group included subjects with low
baseline levels of LDL, as defined according to ATPIII
(85). A greater decrease in LDL levels was observed in
subjects with optimal to borderline high levels of baseline
LDL. The LDL cholesterol levels of the former decreased
by 0.37 mmol/L (95% CI: 0.42, 0.31) and those
of the latter decreased by 0.28 mmol/L (95% CI: 0.31,
0.25). The placebo adjusted reduction in LDL levels
produced by consumption of plant sterols was the same
across all age groups.
There was evidence of a dose response effect. The
minimum (0.25 mmol/L; 95% CI: 0.32, 0.18) and
the maximum (0.42 mmol/L; 95% CI: 0.46, 0.39)
reductions in LDL cholesterol levels were achieved by the
intake of B1.5g/ day and  2.5 g/ day of sterols/stanols,
respectively. The reductions in LDL were 0.29 mmol/L
(95% CI: 0.34, 0.24) and0.32mmol/L (95% CI:
0.36, 0.28) for intakes of 1.52.0 g/d and 2.12.5 g/d,
respectively.
Table 1. Calculation of Jadad score to assess study quality
1
Criterion Score
If study was described as randomized (this includes
words such as randomly, random, and randomization)
0/1
If the method used to generate the sequence of
randomization was described and was appropriate
(table of random numbers, computer-generated, etc.)
0/1
Deduct one point if the method used to generate the
sequence of randomization was described and it was
inappropriate (patients were allocated alternately, or
according to date of birth, hospital number, etc.)
0/1
If the study was described as double blind 0/1
If the method of double blinding was described and was
appropriate (identical placebo, active placebo, dummy, etc.)
0/1
Deduct one point if the study was described as double blind
but the method of blinding was inappropriate
(e.g., comparison of tablet versus. injection with no
double dummy).
0/1
If there was a description of withdrawals and dropouts 0/1
1Adapted from Jadad et al. (40).
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(page number not for citation purpose)Table 2. Design and subject characteristics of randomized controlled studies of plant sterols/stanols
Study ID Reference Design
Duration
weeks n Subjects
1 Sex
2
Age
years
BMI
3
kg/m
2
AbuMweis et al. (2006a) (32) crossover 4 30 borderline high NR 59 2529.9
AbuMweis et al. (2006b) (32) crossover 4 30 borderline high NR 59 2529.9
Algorta Pineda et al. (2005) (34) parallel 3 32 high 5095% males 42 2529.9
Alhassan et al. (2006) (60) parallel 5 26 near or above
optimal
550% males 53Tx 52Co 2529.9
Andersson et al. (1999) (13) parallel 8 40 high 550% males 55 2529.9
Ayesh et al. (1999) (61) parallel 3 & 4 21 optimal 550% males 36 B24.9
Cater et al. (2005a) (62) crossover 6 8 NR 5095% males 58 2529.9
Cater et al. (2005b) (62) crossover 6 8 NR 5095% males 58 2529.9
Cater et al. (2005c) (62) crossover 6 8 NR 5095% males 58 2529.9
Cater et al. (2005d) (62) crossover 8 10 near or above
optimal
 95% males 66 2529.9
Christiansen et al. (2001a) (63) parallel 26 92 high NR 51 B24.9
Christiansen et al. (2001b) (63) parallel 26 89 high NR 51 2529.9
Cleghorn et al. (2003) (64) crossover 4 50 borderline high 550% males 47 2529.9
Davidson et al. (2001a) (28) parallel 8 42 borderline high 5095% males; 46 NR
Davidson et al. (2001b) (28) parallel 8 40 borderline high 5095% males; 46 NR
Davidson et al. (2001c) (28) parallel 8 44 borderline high 5095% males; 46 NR
De Graaf et al. (2002) (47) parallel 4 62 high 5095% males; 56 Tx 58 Co 2529.9
Deavarj et al. (2006) (22) parallel 8 72 borderline high 550% males 44 Tx 48 Co B24.9
Devaraj et al. (2004) (23) parallel 8 72 borderline high 550% males 41 Tx 44 Co 2529.9
Doornbos et al. (2006a) (19) parallel 4 72 borderline high 550% males 57 2529.9
Doornbos et al. (2006b) (19) parallel 4 71 borderline high 550% males 57 2529.9
Doornbos et al. (2006c) (19) parallel 4 69 borderline high 550% males 57 2529.9
Doornbos et al. (2006d) (19) parallel 4 71 borderline high 550% males 57 2529.9
Gylling et al. (1994) (65) crossover 6 11 NR  95% males 58 2529.9
Gylling et al. (1999) (66) crossover 5 21 borderline high B5% males 53 2529.9
Hallikainen et al. (1999a) (10) parallel 8 37 high 550% males 41 Tx 46 Co B24.9 Tx
2529.9 Co
Hallikainen et al. (1999b) (10) parallel 8 35 high 550% males 43 Tx 46 Co 2529.9
Hallikainen et al. (2000a) (67) crossover 4 34 high NR 49 B24.9
Hallikainen et al. (2000b) (67) crossover 4 34 high NR 49 B24.9
Hendriks et al. (1999a) (12) crossover 3.5 80 near or above
optimal
550% males 37 B24.9
Hendriks et al. (1999b) (12) crossover 3.5 80 near or above
optimal
550% males 37 B24.9
Hendriks et al. (1999c) (12) crossover 3.5 80 near or above
optimal
550% males 37 B24.9
Hendriks et al. (2003) (68) parallel 52 185 borderline high 550% males 48 B24.9
Hyun et al. (2005) (18) parallel 4 51 near or above optimal 5095% males; 29 B24.9
Jakulj et al. (2005) (69) crossover 4 39 very high 5095% males; 56 2529.9
Jones et al. (1999) (54) parallel 4.3 32 high & very high  95% males NR NR
Jones et al. (2000a) (50) crossover 3 15 high  95% males NR NR
Jones et al. (2000b) (50) crossover 3 15 high  95% males NR NR
Jones et al. (2003a) (27) crossover 3 15 borderline high 5095% males NR NR
Jones et al. (2003b) (27) crossover 3 15 borderline high 5095% males NR NR
Judd et al. (2002) (70) crossover 3 53 borderline high 550% males 47 2529.9
Jauhianen et al. (2006) (49) parallel 5 67 borderline high 550% males 43 NR
Lau et al. (2005a) (71) crossover 3 15 borderline high 550% males 55 2529.9
Lau et al. (2005b) (71) crossover 3 14 borderline high 550% males 55 3034.9
Plant sterols enriched foods and LDL levels
5
(page number not for citation purpose)Table 2 (Continued)
Study ID Reference Design
Duration
weeks n Subjects
1 Sex
2
Age
years
BMI
3
kg/m
2
Lee et al. (2003) (72) parallel 12 81 high 550% males 60 TX 62 Co 2529.9
Lottenberg et al. (2003) (73) crossover 4 60 very high 550% males NR NR
Maki et al. (2001a) (37) parallel 5 158 borderline high 550% males 59 Tx 58 Co 2529.9
Maki et al. (2001b) (37) parallel 5 118 borderline high 550% males 60 Tx 58 Co 2529.9
Matvienko et al. (2002) (33) parallel 4 34 borderline high  95% males 22 Tx 22 Co 2529.9
Mensink et al. (2002) (20) parallel 4 60 near or above optimal 550% males 36 B24.9
Miettinen and Vanhanen
(1994a)
(45) parallel 9 17 NR 5095% males 45 2529.9
Miettinen and Vanhanen
(1994b)
(45) parallel 9 15 NR 5095% males 45 2529.9
Miettinen and Vanhanen
(1994c)
(45) parallel 9 15 NR 5095% males 45 2529.9
Mussner et al. (2002) (35) crossover 3 63 borderline high 550% males 42 B24.9
Naumann et al. (2003a) (36) crossover 3 42 near or above
optimal
550% males 32 w 37 m B24.9
crossover
Naumann et al. (2003b) (36) crossover 3 42 near or above
optimal
550% males 32 w 37 m B24.9
Neil et al. (2001) (74) crossover 8 29 very high 550% males 53 Tx 50 Co 2529.9
Nguyen et al. (1999a) (75) parallel 8 159 borderline high 550% males 53 2529.9
Nguyen et al. (1999b) (75) parallel 8 157 borderline high 550% males 53 2529.9
Nguyen et al. (1999c) (75) parallel 8 162 borderline high 550% males 53 2529.9
Nigon et al. (2001) (76) crossover 8 53 borderline high & high 550% males 58 B 24.9
Noakes et al. (2002a) (77) crossover 3 46 high 550% males 58 w 55 m 2529.9
Noakes et al. (2002b) (77) crossover 3 46 high 550% males 58 w 55 m 2529.9
Noakes et al. (2002c) (77) crossover 3 35 high 5095% males 56 w 58 m 2529.9
Noakes et al. (2005a) (16) crossover 3 40 high 550% males 60 2529.9
Noakes et al. (2005b) (16) crossover 3 40 high 550% males 60 2529.9
Ntanios et al. (2002) (38) crossover 3 53 near or above optimal 550% males 45 B24.9
Plat and Mensink et al.
(2000a)
(78) parallel 8 78 near or above optimal 550% males 33 B24.9
Plat and Mensink et al.
(2000b)
(78) parallel 8 76 near or above optimal 550% males 33 B24.9
Plat et al. (2000a) (31) crossover 4 39 optimal 550% males 31 B24.9
Plat et al. (2000b) (31) crossover 4 39 optimal 550% males 31 B24.9
Polagruto et al. (2006) (48) parallel 6 67 high 550% males 49 Tx 56 Co 2529.9
Quilez et al. (2003) (21) parallel 8 57 optimal 550% males 31 B24.9
Saito et al. (2006a) (79) parallel 4 33 borderline high  95% males 38 Tx 39 Co B24.9
Saito et al. (2006b) (79) parallel 4 33 borderline high  95% males 39 B24.9
Saito et al. (2006c) (79) parallel 4 34 borderline high  95% males 38 Tx 39 Co B24.9
Seki et al. (2003) (43) parallel 12 60 borderline high  95% males 39 B24.9
Sierksma et al. (1999) (80) crossover 3 75 NR 5095% males 44 B24.9
Simons et al. (2002) (42) parallel 4 77 very high 5095% males 58 Tx 60 Co 2529.9
Spilburg et al. (2003) (26) parallel 4 24 borderline high 5095% males 51 2529.9
Temme et al. (2002) (81) crossover 4 42 high 5095% males 55 2529.9
Thomsen et al. (2004a) (15) crossover 4 69 high 550% males 60 2529.9
Thomsen et al. (2004b) (15) crossover 4 69 high 550% males 60 2529.9
Vanhanen et al. (1993) (82) parallel 6 67 borderline high 5095% males 48 Tx 43 Co 2529.9
Vanhanen et al. (1994) (83) parallel 6 14 borderline high 550% males 55 2529.9
Vanstone et al. (2002a) (51) crossover 3 15 high 5095% males 48 3034.9
Vanstone et al. (2002b) (51) crossover 3 15 high 5095% males 48 3034.9
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is influenced by the food carrier to which plant sterols/
stanols are incorporated. We predefined the food product
groups according to their fat content, i.e. low fat products
contain 3 g or less fat per serving, as well as their physical
form, i.e liquid versus solid. Therefore, we ended up with
four groups, i.e. fat spreads, mayonnaise and salad
dressing, milk and yoghurt, and other food group. Other
food products subgroup included studies testing the
efficacy of plant sterols/stanols incorporated in chocolate,
cereal bars, beverages, juices, meat, and croissants and
muffins. All these were included in one subgroup and not
further analyzed because of an insufficient number of
clinical trials.
Plant sterols/stanols incorporated into fat spreads,
mayonnaise and salad dressing or milk and yoghurt
reduced LDL cholesterol levels to a greater extent than
plant sterols/stanols incorporated into other food pro-
ducts. Compared to control, LDL levels were reduced by
0.33 (95% CI, 0.38 to 0.28), 0.32 (95% CI, 0.40
to 0.25), 0.34 (95% CI, 0.40 to 0.28) and 0.20
(95% CI, 0.28 to 0.11) mmol/L in the fat spreads,
mayonnaise and salad dressing, milk and yoghurt, and
other food products, respectively. Other food product
subgroups included studies testing the efficacy of plant
sterols/stanols incorporated in chocolate (47, 48), orange
juice (22, 23), cheese (49), non-fat beverage (26, 27), meat
(33), croissants and muffins (21), oil in bread (43), and
cereal bars (24).
The favorable effect of plant sterols/stanols on LDL
cholesterol levels was also shown to be influenced by the
frequency and time of intake of plant sterols. For
instance, plant sterols/stanols consumed 23 times/day
reduced LDL cholesterol levels by 0.34 mmol/L (95% CI:
0.38, 0.18) while plant sterols/stanols consumed
once per day in the morning did not result in a significant
reduction in LDL levels. On the other hand, plant sterols/
stanols consumed once/day with lunch or the principal
meal reduced LDL levels by 0.30 mmol/L (95%: 0.39,
0.21).
We found no evidence of publication bias in this meta-
analysis, as indicated by the funnel plot symmetry (Fig. 3).
Discussion
The present meta-analysis is the first systematic quanti-
tative review of randomized clinical trials yielding
information on factors that might affect efficacy of plant
sterols/stanols as cholesterol lowering agents. Since the
meta-analyses of Law (4) and Katan et al. (5) examining
plant sterol/stanol effects on circulating cholesterol levels,
several studies have been conducted examining the action
of various plant sterol/stanol containing products on
blood cholesterol levels using different study designs. The
present work shows that the intake of plant sterol/stanol
containing food products was associated with a signifi-
cant decrease in LDL cholesterol (0.31 mmol/L).
However, the substantial heterogeneity among individual
trials indicates that the effects of plant sterols/stanols on
LDL cholesterol levels are not uniform.
A larger reduction in LDL cholesterol levels was
observed in subjects with a high to very high baseline
levels of LDL, compared to those with optimal to
borderline high baseline levels. Some previous (35, 36),
but not other studies (8, 37, 38), have reported that the
higher the baseline levels of LDL-cholesterol the more
the reduction in LDL due to plant sterols consumption.
The present meta-analysis has confirmed that baseline
LDL cholesterol levels affect magnitude of reduction in
LDL after plant sterol/stanol consumption which could
explain the wide variation in responsiveness seen in
previous studies. Nevertheless, plant sterols/stanols do
reduce LDL levels in individuals with normal to high
baseline LDL levels as well as in adults across different
age groups. Therefore, everyone, excluding individuals
Table 2 (Continued)
Study ID Reference Design
Duration
weeks n Subjects
1 Sex
2
Age
years
BMI
3
kg/m
2
Vanstone et al. (2002c) (51) crossover 3 15 high 5095% males 48 3034.9
Vissers et al. (2000) (84) crossover 3 60 NR 550% males NR NR
Volpe et al. (2001) (17) crossover 4 30 high 5095% males NR B24.9
Weststrate et al. (1998a) (8) crossover 3.5 95 borderline high 50% males 45 B24.9
Weststrate et al. (1998b) (8) crossover 3.5 95 borderline high 50% males 45 B24.9
Yoshida et al. (2006a) (24) crossover 3 16 high 550% males 55 2529.9
Yoshida et al. (2006b) (24) crossover 3 13 borderline high 550% males 57 3034.9
NR not reported, NC Not clear, Tx treatment; Co control; w women; mmen.
1 Subjects were classified according to total or LDL cholesterol baseline levels reported in baseline characteristic. Classification based on ATPIII (85).
2 Predominant sex.
3Body Mass Index.
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Plant sterols/stanols
Study ID Reference Carrier
1 Type
2 Dose g/day as free Frequency Time
3
AbuMweis et al. (2006a) (32) margarine free sterols 1.7 1 at breakfast
AbuMweis et al. (2006b) (32) margarine sterol esters 1.7 1 at breakfast
Algorta Pineda et al.
(2005)
(34) yoghurt stanol esters 2.0 1 with the main meal
Alhassan et al. (2006) (60) margarine stanol esters NR NR NR
Andersson et al. (1999 (13) margarine stanol esters 1.9 NR NR
Ayesh et al. (1999) (61) margarine sterol esters 8.6 2 breakfastsupper
Cater et al. (2005a) (62) margarine stanol esters 2.0 3 with each meal
Cater et al. (2005b) (62) margarine stanol esters 3.0 3 with each meal
Cater et al. (2005c) (62) margarine stanol esters 4.0 3 with each meal
Cater et al. (2005d) (62) margarine stanol esters 3.0 3 with each meal
Christiansen et al.
(2001a)
(63) margarine free sterols 1.5 at least 2 NR
Christiansen et al.
(2001b)
(63) margarine free sterols 3.0 at least 2 NR
Cleghorn et al. (2003) (64) margarine sterol esters 2.0 NR NR
Davidson et al. (2001a) (28) margarine sterol esters 3.0 NR NR
Davidson et al. (2001b) (28) salad dressing sterol esters 6.0 NR NR
Davidson et al. (2001c) (28) spreadsalad dressing sterol esters 9.0 NR NR
De Graaf et al. (2002) (47) chocolate bars free sterols 1.8 3 with each meal
Deavarj et al. (2006) (22) Orange juice free sterols 2.0 2 breakfastsupper
Devaraj et al. (2004) (23) Orange juice free sterols 2.0 2 NR
Doornbos et al. (2006a) (19) yoghurt sterol esters 3.2 1 at breakfast
Doornbos et al. (2006b) (19) yoghurt sterol esters 3.2 1 at lunch
Doornbos et al. (2006c) (19) yoghurt sterol esters 2.8 1 at breakfast
Doornbos et al. (2006d) (19) yoghurt sterol esters 2.8 1 at lunch
Gylling et al. (1994) (65) margarine stanol esters 3.0 3 at breakfastlunch
supper
Gylling et al. (1999) (66) dairy spread stanol esters 2.5 NR NR
Hallikainen et al.
(1999a)
(10) margarine stanol esters 2.2 NR NR
Hallikainen et al.
(1999b)
(10) margarine stanol esters 2.3 NR NR
Hallikainen et al.
(2000a)
(67) margarine sterol esters 2.1 2 to 3 NR
Hallikainen et al.
(2000b)
(67) margarine stanol esters 2.0 2 to 3 NR
Hendriks et al. (1999a) (12) margarine sterol esters 0.8 2 at lunch and supper
Hendriks et al. (1999b) (12) margarine sterol esters 1.6 2 at lunch and supper
Hendriks et al. (1999c) (12) margarine sterol esters 3.2 2 at lunch and supper
Hendriks et al. (2003) (68) margarine sterol esters 1.6 2 at breakfastlunch
or supper
Hyun et al. (2005) (18) yoghurt stanol esters 2.0 1 at breakfast
Jakulj et al. (2005) (69) margarine sterol esters 2.0 NR NR
Jones et al. (1999) (54) margarine free sterols 1.7 3 at breakfastlunch
supper
Jones et al. (2000a) (50) margarine sterol esters 1.8 3 at breakfastlunch
supper
S. S. AbuMweis et al.
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Plant sterols/stanols
Study ID Reference Carrier
1 Type
2 Dose g/day as free Frequency Time
3
Jones et al. (2000b) (50) margarine stanol esters 1.8 3 at breakfastlunch
supper
Jones et al. (2003a) (27) beverage free sterols 1.8 3 at breakfastlunch
supper
Jones et al. (2003b) (27) beverage free sterols 1.8 3 at breakfastlunch
supper
Judd et al. (2002) (70) salad dressing sterol esters 2.2 2 at lunch and supper
Jauhianen et al. (2006) (49) soft cheese stanol esters 2 1 or 2 at lunch or with the
main meal
Lau et al. (2005a) (71) margarine free sterols 1.8 1 at breakfast
Lau et al. (2005b) (71) margarine free stanols 1.8 1 at breakfast
Lee et al. (2003) (72) margarine sterol esters 1.6 2 breakfastsupper
Lottenberg et al. (2003) (73) margarine sterol esters 1.7 3 at breakfastlunch
supper
Maki et al. (2001a) (37) margarine sterol esters 1.1 2 NR
Maki et al. (2001b) (37) margarine sterol esters 2.2 2 NR
Matvienko et al. (2002) (33) meat sterol esters 2.7 1 at lunch
Mensink et al. (2002) (20) yoghurt stanol esters 3.0 2 or 3 with each meal or
breakfastsupper
Miettinen and
Vanhanen (1994a)
(45) mayonnaise free sterols 0.7 NR NR
Miettinen and
Vanhanen (1994b)
(45) mayonnaise free stanols 0.7 NR NR
Miettinen and
Vanhanen (1994c)
(45) mayonnaise stanol esters 0.8 NR NR
Mussner et al. (2002) (35) margarine sterol esters 1.8 2 breakfastsupper
Naumann et al. (2003a) (36) margarine mixture of sterol and
stanol esters
2.0 NR NR
Naumann et al. (2003b) (36) margarine mixture of sterol and
stanol esters
2.0 NR NR
Neil et al. (2001) (74) margarine sterol esters 2.5 NR NR
Nguyen et al. (1999a) (75) margarine stanol esters 3.0 3 NR
Nguyen et al. (1999b) (75) margarine stanol esters 3.0 3 NR
Nguyen et al. (1999c) (75) margarine stanol esters 2.0 3 NR
Nigon et al. (2001) (76) margarine sterol esters 1.6 3 at breakfastlunch
supper
Noakes et al. (2002a) (77) margarine sterol esters 2.3 3 at breakfastlunch
supper
Noakes et al. (2002b) (77) margarine stanol esters 2.5 3 at breakfastlunch
supper
Noakes et al. (2002c) (77) margarine sterol esters 2.0 3 at breakfastlunch
supper
Noakes et al. (2005a) (16) yoghurt sterol esters 1.8 2 NR
Noakes et al. (2005b) (16) yoghurt stanol esters 1.7 2 NR
Ntanios et al. (2002) (38) margarine sterol esters 1.8 2 at breakfastlunch
or supper
Plat and Mensink
et al. (2000a)
(78) margarine stanol esters 3.8 3 at breakfastlunch
supper
Plat and Mensink
et al. (2000b)
(78) margarine stanol esters 4.0 3 at breakfastlunch
supper
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can reduce his/her blood cholesterol levels by consuming
plant sterols/stanols.
A positive dose response relationship was apparent
with the greatest reduction in LDL levels obtained with
intakes of 2.5 g/day of plant sterols/stanols. The meta-
analysis by Katan et al. (5) showed that there is little
additional effect of plant sterols/stanols at doses higher
than 2.5 g/day. It should be noted that studies included in
the subgroups with intakes ]2.1 g/day incorporated
plant sterols/stanols mainly in fat spreads, while the other
subgroups included a variety of food products, which
could explain why heterogeneity was absent with intakes
of ]2.1g/ day.
Plant sterols/stanols reduce LDL cholesterol through
interfering with cholesterol absorption (9, 5052). Be-
cause of their inert crystalline structure, pure plant
sterols/stanols are not consistently effective in lowering
cholesterol absorption. Thus, plant sterols/stanols should
be adequately formulated before use. The most accepted
method used to optimize the effect of plant sterols/stanols
on cholesterol absorption is esterification to fatty acids
Table 3 (Continued)
Plant sterols/stanols
Study ID Reference Carrier
1 Type
2 Dose g/day as free Frequency Time
3
Plat et al. (2000a) (31) margarine stanol esters 2.5 1 at lunch
Plat et al. (2000b) (31) margarineshortening
in cakes and cookies
stanol esters 2.5 3 at breakfastlunch
supper
Polagruto et al. (2006) (48) chocolate bars sterol esters 1.5 2 between meals
Quilez et al. (2003) (21) croissants and muffins sterol esters 3.2 2 NR
Saito et al. (2006a) (79) mayonnaise sterol esters 0.3 1 NR
Saito et al. (2006b) (79) mayonnaise sterol esters 0.4 1 NR
Saito et al. (2006c) (79) mayonnaise sterol esters 0.5 1 NR
Seki et al. (2003) (43) vegetable oil sterol esters 0.5 3 NR
Sierksma et al. (1999) (80) margarine free sterols 0.8 NR NR
Simons et al. (2002) (42) margarine sterol esters 2.0 2 NR
Spilburg et al. (2003) (26) beverage stanol lecithin 1.9 3 at breakfastlunch
supper
Temme et al. (2002) (81) margarine sterol esters 2.0 3 at breakfastlunch
supper
Thomsen et al. (2004a) (15) milk free sterols 1.2 2 at breakfastlunch
Thomsen et al. (2004b) (15) milk free sterols 1.6 2 at breakfastlunch
Vanhanen et al. (1993) (82) mayonnaise stanol esters 3.4 NR NR
Vanhanen et al. (1994) (83) mayonnaise stanol esters 1.5 NR NR
Vanstone et al. (2002a) (51) dairy spread free sterols 1.8 3 at breakfastlunch
supper
Vanstone et al. (2002b) (51) dairy spread free stanols 1.8 3 at breakfastlunch
supper
Vanstone et al. (2002c) (51) dairy spread mixture of free sterols
and stanols
1.8 3 at breakfastlunch
supper
Vissers et al. (2000) (84) margarine free sterols 2.1 NR NR
Volpe et al. (2001) (17) yoghurt free sterols 1.0 1 NR
Weststrate et al.
(1998a)
(8) margarine sterol esters 3.2 2 at lunch and supper
Weststrate et al.
(1998b)
(8) margarine stanol esters 2.7 2 at lunch and supper
Yoshida et al. (2006a) (24) cereals bars free sterols 1.8 3 between meals
Yoshida et al. (2006b) (24) cereals bars free sterols 1.8 3 between meals
NR not reported.
1Food carrier to which plant sterols/stanols were added.
2Type of plant sterols/ stanols.
3Time of consumption of plant sterol/stanol enriched products.
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Some studies have shown that free plant sterols/stanols
when mixed with fat spread are also effective in reducing
LDL cholesterol levels (51, 54). Later on, plant sterols/
stanols were added to low and non- fat food products.
The results presented here show that comparedwith plant
sterol/stanol containing fat spreads, mayonnaise and
salad dressing, and milk and yoghurt, other plant
sterol/stanol containing food products, including choco-
late (47, 48), orange juice (22, 23), cheese (49), non-fat
beverage (26, 27), meat (33), croissants and muffins (21),
oil in bread (43), and cereal bars (24) demonstrated less
of a LDL-reduction efficacy. This finding highlights the
importance of food carrier and proper formulation of
plant sterols/stanols. Although milk and yoghurt drinks
contain much less fat than fat spreads and mayonnaise,
milk and yoghurt drinks demonstrated similar efficacy as
of products with higher fat content. Thus, the food
carrier to which plant sterols/stanols are added does not
have to contain a high fat content to be an effective
means of release of plant sterols/stanols to compete with
cholesterol absorption, given that a proper plant sterol
formulation is provided. Unfortunately, exact methods
used to formulate plant sterols/stanols in the milk and
yoghurt studies are not described in adequate detail.
Studies were reported only if they used free (15, 17) or
esterified (16, 1820, 34) sterols or stanols. It is also
possible that plant sterols/stanols in milk may be more
readily incorporated into milk globule membranes, thus
more readily compete with cholesterol for transfer into
the micelles, while in the other low fat foods plant sterols/
stanols may be trapped in the centre of the lipid droplets
and not be available until the fat is digested (30). Future
work is needed to identify proper formulation of plant
sterols/stanols to improve their efficacy in food products
other than those with high fat contents, i.e. vegetable and
dairy spreads and mayonnaise, or milk and yoghurts.
In a previous study from our group, consumption of a
single dose of different preparations of plant sterols in the
morning failed to lower LDL levels (32). Some studies
have shown that consumption of single dose of plant
sterols/stanols with lunch lowered LDL levels (31, 33).
One study has tested the efficacy of plant stanol
consumed at different frequencies. In the study by Plat
et al. (31) subjects consumed the plant stanol enriched
margarine at breakfast and at lunch and ate a cake or
cookie containing plant stanol-enriched shortening
within one hour after supper. The higher portion of
plant stanol during the 3 times/day phase was given using
a different food carrier and was consumed without a meal
in comparison to the single dose phase, thus, multiple
factors might contribute to the differences in results
obtained between the study phases. Additionally, the
availability of plant stanol in the cakes and cookies might
be affected by baking conditions. To what extent this
affected the cholesterol lowering action of 3 times/day
phase of plant stanol intake is unknown. To examine that
question, we conducted a subgroup analysis looking at
frequency and time of intake of plant sterols/stanols. The
results of this meta-analysis show that the time of intake
of a single dose of plant sterols/stanols may affect their
cholesterol- lowering action as consumption of single
dose with lunch or main meal, but not before or with
breakfast, lowered LDL levels. The results of the
subgroup analyses examining time of intake of plant
sterols/stanols should be interpreted with caution, how-
ever. The number of subjects included in the individual
subgroups was small and many of the included studies
did not report data on time of intake, resulting in the
potential to be misled by bias. The exact mechanisms
responsible for the effects of plant sterols/stanols on LDL
levels are still being investigated. Based on current
knowledge, plant sterols/stanols reduce solubilization of
cholesterol in micelles and also may affects the site of
Fig. 2. Effect size and 95% CI in LDL cholesterol levels
associated with consumption of plant sterol/stanol contain-
ing food products.
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(55).
The efficacy of plant sterols/stanols as a cholesterol-
lowering agent may demonstrate a time-of-day variation,
possibly coinciding with the diurnal rhythm of cholesterol
metabolism. Diurnal rhythm in cholesterol synthesis has
been shown in humans (5658), where cholesterol frac-
tional synthetic rate values peaked at 6:00 h and were
lowest during the daytime period. Moreover, bile acid
synthesis in humans has also a diurnal rhythm that is
opposite from the diurnal rhythm of cholesterol synthesis
(59). Therefore, until mechanisms have been elucidated by
which plant sterols/stanols and in particular single dose
of plant sterols/stanols reduce LDL levels, and until there
are more studies on consumption of plant sterols/stanols
as single dose; plant sterols should be consumed in two to
three portions per day.
In conclusion, plant sterol/stanol containing products
significantly reduced LDL concentrations but the reduc-
tion was related to individuals’ baseline LDL levels, food
carrier, frequency and time of intake.
Conflict of Interest and Funding
The contribution of the authors were as follow: SSA
designed and implemented the search strategy, assessed
study quality, extracted data, performed statistical ana-
lysis, interpreted the results and wrote and edited the
manuscript. RIB was involved in literature search, study
selection and quality assessment, and data extraction.
PJHJ provided guidance and critical revision of the
manuscript. We would like to thank Mrs Mary Cheang,
a statistical consultant at the Department of Community
Health Sciences, University of Manitoba, for reviewing
Table 4. Pooled estimates of treatment effect on LDL cholesterol in subgroups of trials deﬁned by subject characteristics and study design
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Variables No. of trials, n Effect size (95% CI) mmol/L P Test of heterogeneity, P
Age (years)
2039 10 0.29 (0.35, 0.23) B0.0001 0.16
4049 15 0.32 (0.41, 0.24) B0.0001 B0.0001
5060 21 0.30 (0.37, 0.23) B0.0001 B0.0001
Baseline LDL cholesterol levels
Optimal to border line high 33 0.28 (0.31,0.25) B0.0001 0.38
High to very high 22 0.37 (0.42, 0.31) B0.0001 0.01
Plant sterol dose (g/day)
B1.5 8 0.25 (0.32, 0.18) B0.0001 0.05
1.52.0 35 0.29 (0.34, 0.24) B0.0001 0.0003
2.12.5 9 0.32 (0.36, 0.28) B0.0001 0.12
2.5 13 0.42 (0.46, 0.39) B0.0001 0.57
Carrier
Fat spreads 38 0.33 (0.38, 0.28) B0.0001 B0.0001
Mayonnaise and salad dressing 6 0.32 (0.40, 0.25) B0.0001 0.3
Milk and yoghurt 7 0.34 (0.40, 0.28) B0.0001 0.18
Other than fat spreads, mayonnaise, salad
dressing and milk and yoghurt
11 0.20 (0.28, 0.11) B0.0001 0.21
Frequency of intake and time of intake
23 times/day 38 0.34 (0.38, 0.18) B0.0001 B0.0001
Once/day in the morning 4 0.14 (0.29, 0.00) 0.05 0.60
Once/ day in the afternoon or with main meal 3 0.30 (0.39, 0.21) B0.0001 0.82
Fig. 3. Funnel plots of SE versus effect size for LDL
cholesterol levels.
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Appendix: Calculations used in the meta-analysis of
plant sterols and LDL-cholesterol levels
Effect size (ES)
For parallel trials, endpoint LDL cholesterol in the
treatment group was subtracted from endpoint LDL
cholesterol in the control group (46). For crossover trials,
LDL cholesterol values at the end of the treatment period
were subtracted from LDL cholesterol values at the end
of the control period (46). Within-individual changes
were used when presented; otherwise, group means were
used. In symbols, the estimates of effect size (ES) are:
 For parallel trials: ESIITf  Cf
where
ESIIthe effect size of a parallel design trial,
Tffinal LDL cholesterol mean in the treatment group
Cffinal LDL cholesterol mean in the control group
 For crossover trials: ESxT  C
where
ESxthe effect size of a crossover design trial
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(page number not for citation purpose)TLDL cholesterol mean at the end of the treatment
period
CLDL cholesterol mean at the end of the control
period
Standard Error (SE) of effect size (ES)
 For parallel trials:
The SE of ES for a parallel study was calculated as
follows
SEII(SDT)
2/nT(SDC)
2/nC
where
SEIISE of effect size for a parallel study
SDTstandard deviation of LDL-cholesterol endpoints
in the treatment group
SDCstandard deviation of LDL-cholesterol endpoints
in the control
nTsample size of the treatment group
nCsample size of the control group
SDs were extracted from the studies or, if not reported,
derived from SE of mean or CI for group mean, (46) as
follows:
 From SE:
Standard error of group meanSD /N
 From CI for group mean:
SDN(upper limitlower limit)/2* t (1-confidence
level, degree of freedom)
where
t (1-confidence level, degree of freedom) is the t -value associate
with study confidence level, usually 95%, and sample size
of group
 For crossover trials (46, 86):
The SE of ES for a crossover study was calculated as
follows
SEx SD (diff)/n
where
SEx standard error of effect size for a crossover study
SD(diff)Standard deviation of difference between the
treatment period and the control period
n sample size
or
SEx was extracted from reported statistical values in the
trial, paired t-value or P-value, CI from a paired analysis
or imputed from a number of studies as follows:
 From t or P-value:
t diff/ SEx
where
diff is mean of difference between control period and
treatment period
If only the exact P-value or the upper bounded P-value of
the paired t-test was reported, then the correspondent t-
value for that P-value was calculated by entering the P-
value and the degree of freedom into a spreadsheet as
follows:tinv(P-value, degree of freedom)
 From CI:
SEx(upper limitlower limit)/2* t(1-confidence level,
degree of freedom)
where
t (1-confidence level, degree of freedom) is the t -value associate
with study confidence level, usually 95%, and degree of
freedom
 From imputed SD (diff):
Imputed SD(diff)(SD
2
TSD
2
C (2RSDTSDC))
where
SD (diff)standard deviation of difference between the
treatment period and the control period
SD
2
TLDL-cholesterol variance at the end of the treat-
ment period
SD
2
CLDL-cholesterol variance at the end of the control
period
R 0.81 which is within-individual correlation between
the treatment and control periods that was calculated
from a number of studies.
Pooled effect size (ES) estimate
Treatment ES and its SE were calculated for every trial as
described above. To obtain the pooled treatment effect
size, the effect size estimates and standards error were
entered into RevMan 4.2 under the ‘‘Generic inverse
variance’’ outcome. In the inverse variance method the
weight given to each study is chosen to be the inverse of
the variance of the effect estimate.
A fixed effect meta-analysis using the inverse variance
method calculates a weighted average as follows:
Generic inverse variance weighted average /
a(ESi=SE
2
i )
a(1=SE
2
i )
where
ESi is the effect size in study i, SEi is the standard error of
that estimate and the summation is across all studies.
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treatment and control periods for crossover studies
SD (mmol/L)
Study ID Control Treatment Difference R
AbuMweis 2006a (32) 0.93 1.01 0.51 0.87
AbuMweis 2006b (32) 0.93 1.06 0.59 0.83
Noakes 2005a (16) 0.74 0.71 0.32 0.91
Noakes 2005b (16) 0.74 0.76 0.32 0.91
Jones 2003a (27) 0.89 1.08 0.64 0.81
Jones 2003b (27) 0.89 0.81 0.51 0.83
Judd 2002 (70) 0.28 0.28 0.28 0.50
Jones 2000a (50) 0.70 0.59 0.40 0.82
Jones 2000b (50) 0.70 0.74 0.39 0.86
Average 0.81
where
R within-individual correlation between the treatment
and control periods and was calculated as follows:
R
(Control SD)
2  (Treatment SD)
2  (Difference SD)
2
2  (Control SD)  (Treatment SD)
Plant sterols enriched foods and LDL levels
17
(page number not for citation purpose)